Details for Patent: 10,065,952
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Which drugs does patent 10,065,952 protect, and when does it expire?
Patent 10,065,952 protects INGREZZA and is included in one NDA.
This patent has thirty-four patent family members in twenty-seven countries.
Summary for Patent: 10,065,952
| Title: | Valbenazine salts and polymorphs thereof |
| Abstract: | Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[- 2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of neurological disorders and diseases including hyperkinetic movement disorders or diseases. |
| Inventor(s): | McGee; Kevin (San Diego, CA), Zook; Scott (San Diego, CA), Carr; Andrew (Cambridge, GB), Bonnaud; Thierry (Cambridge, GB) |
| Assignee: | Neurocrine Biosciences, Inc. (San Diego, CA) |
| Application Number: | 15/338,214 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,065,952 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Dosage form; |
Drugs Protected by US Patent 10,065,952
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Sign Up | ||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Sign Up | ||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,065,952
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016343633 | ⤷ Sign Up | |||
| Brazil | 112018008460 | ⤷ Sign Up | |||
| Canada | 3002074 | ⤷ Sign Up | |||
| Chile | 2018001089 | ⤷ Sign Up | |||
| China | 108473489 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
